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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to various 
microorganisms and changes in bowel function, and digestion and 
absorption of nutrients (ID 960, 961, 967, 969, 971, 975, 983, 985, 994, 996, 
998, 1006, 1014), decreasing potentially pathogenic gastro-intestinal 
microorganisms (ID 960, 967, 969, 971, 975, 983, 985, 994, 996, 998, 1006, 
1014), and stimulation of immunological responses (ID 962, 968, 970, 972, 
976, 984, 986, 995, 997, 999, 1007, 1015) (further assessment) pursuant to 
Article 13(1) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies 
(NDA) was asked to provide a scientific opinion on health claims pursuant to Article 13 of Regulation (EC) No 
1924/2006 in the framework of further assessment related to various microorganisms and changes in bowel 
function, and digestion and absorption of nutrients, decreasing potentially pathogenic gastro-intestinal 
microorganisms, and stimulation of immunological responses. The food constituents, Bifidobacterium animalis 
subsp. lactis THT 010801, Bifidobacterium longum subsp. infantis THT 010201, Bifidobacterium longum subsp. 
longum THT 010301, Bifidobacterium pseudolongum subsp. pseudolongum THT 010501, Lactobacillus casei 
THT 030401, Lactobacillus gasseri THT 031301, Lactobacillus helveticus THT 031102, Lactobacillus 
plantarum THT 030701, Lactobacillus plantarum THT 030707, Lactobacillus reuteri THT 030802, 
Lactobacillus salivarius THT 031001 and Streptococcus thermophilus THT 070102, are sufficiently 
characterised. The evidence provided did not establish that the proposed claimed effect, stimulation of 
immunological responses, is a beneficial physiological effect. The references provided for the health claims 
related to changes in bowel function and decreasing potentially pathogenic gastro-intestinal microorganisms 
included studies which assessed the effects of food constituents other than the food constituents which are the 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2012-00133, EFSA-Q-2012-00134, EFSA-Q-2012-
00135, EFSA-Q-2012-00136, EFSA-Q-2012-00137, EFSA-Q-2012-00138, EFSA-Q-2012-00139, EFSA-Q-2012-00140, 
EFSA-Q-2012-00141, EFSA-Q-2012-00142, EFSA-Q-2012-00143, EFSA-Q-2012-00144, EFSA-Q-2012-00145, EFSA-
Q-2012-00146, EFSA-Q-2012-00147, EFSA-Q-2012-00148, EFSA-Q-2012-00149, EFSA-Q-2012-00150, EFSA-Q-2012-
00151, EFSA-Q-2012-00152, EFSA-Q-2012-00153, EFSA-Q-2012-00154, EFSA-Q-2012-00155, EFSA-Q-2012-00158, 
EFSA-Q-2012-00159, adopted on 28 June 2012. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank the members of the Working Group on Claims for the preparatory work on 
this scientific opinion: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina 
Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, 
Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen. 
 
Health claims related to various microorganisms (further assessment) 
 
2 EFSA Journal 2012;10(8):2857 
subject of the claims and/or investigated health outcomes unrelated to the claimed effects. No human studies 
which investigated the effects of the food constituents on appropriate measures of the claimed effects were 
provided. On the basis of the data presented, the Panel concludes that a cause and effect relationship has not been 
established between the consumption of the food constituents and the claimed effects evaluated in this opinion.  
© European Food Safety Authority, 2012 
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SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies (NDA) was asked to provide a scientific opinion on a list of health claims pursuant to Article 
13 of Regulation (EC) No 1924/2006. The Commission has agreed with EU Member States that a 
certain number of Article 13 health claims would be eligible for further assessment by EFSA in order 
to be able to take a final decision on whether or not to include these claims in the list of permitted 
health claims. This opinion addresses the scientific substantiation of health claims in relation to 
various microorganisms and changes in bowel function, and digestion and absorption of nutrients, 
decreasing potentially pathogenic gastro-intestinal microorganisms, and stimulation of immunological 
responses. The scientific substantiation is based on the information provided by the competent 
Authority of Belgium for further assessment of these claims. 
The following food constituents are sufficiently characterised: 
Bifidobacterium animalis subsp. lactis THT 010801 (ID 960, 961, 962), 
Bifidobacterium longum subsp. infantis THT 010201 (ID 967, 968), 
Bifidobacterium longum subsp. longum THT 010301 (ID 969, 970), 
Bifidobacterium pseudolongum subsp. pseudolongum THT 010501 (ID 971, 972), 
Lactobacillus casei THT 030401 (ID 975, 976), 
Lactobacillus gasseri THT 031301 (ID 983, 984), 
Lactobacillus helveticus THT 031102 (ID 985, 986), 
Lactobacillus plantarum THT 030701 (ID 994, 995), 
Lactobacillus plantarum THT 030707 (ID 996, 997), 
Lactobacillus reuteri THT 030802 (ID 998, 999), 
Lactobacillus salivarius THT 031001 (ID 1006, 1007), 
Streptococcus thermophilus THT 070102 (ID 1014, 1015). 
Changes in bowel function, and digestion and absorption of nutrients (ID 960, 961, 967, 969, 971, 
975, 983, 985, 994, 996, 998, 1006, 1014) 
The claimed effects, which are proposed for further assessment, relate to “contribute to the secretion 
and absorption of nutrients”, “degrade indigestible substances (sugars, etc.) into lactic acid and volatile 
fatty acids”, “they participate in mobility intestinal” and “improve the intestinal transit”. The claimed 
effect “contribute to the secretion and absorption of nutrients” is not sufficiently defined and it was not 
possible to establish for which nutrients an improved digestion and absorption is claimed. The claimed 
effect “degrade indigestible substances (sugars, etc.) into lactic acid and volatile fatty acids” is 
assumed to refer to changes in short chain fatty acid (SCFA) and lactic acid production. Changes in 
SCFA and lactic acid production in the gastro-intestinal tract are not beneficial physiological effects 
per se, but need to be linked to a beneficial physiological or clinical outcome. The claimed effects 
“they participate in mobility intestinal” and “improve the intestinal transit” are assumed to refer to 
changes in bowel function. Changes in bowel function such as reduced transit time, more frequent 
bowel movements, increased faecal bulk, or softer stools may be a beneficial physiological effect, 
provided that these changes do not result in diarrhoea.  
No human studies were provided from which conclusions could be drawn for the scientific 
substantiation of the claims. 
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On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of the food constituents which are the subject of the claims 
and changes in bowel function. 
Decreasing potentially pathogenic gastro-intestinal microorganisms (ID 960, 967, 969, 971, 975, 
983, 985, 994, 996, 998, 1006, 1014) 
The claimed effect, which is proposed for further assessment, relates to a decrease in potentially 
pathogenic gastro-intestinal microorganisms. The proposed target population is the general population. 
Decreasing potentially pathogenic gastro-intestinal microorganisms might be a beneficial 
physiological effect. 
No human studies were provided from which conclusions could be drawn for the scientific 
substantiation of the claims. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of the food constituents which are the subject of the claims 
and decreasing potentially pathogenic gastro-intestinal microorganisms. 
Stimulation of immunological responses (ID 962, 968, 970, 972, 976, 984, 986, 995, 997, 999, 1007, 
1015) 
The claimed effect, which is proposed for further assessment, relates to the stimulation of various 
immunological responses. The proposed target population is the general population. The Panel notes 
that stimulation of immunological responses is not a beneficial physiological effect per se, but needs 
to be linked to a beneficial physiological or clinical outcome.  
The Panel considers that the evidence provided did not establish that stimulation of immunological 
responses is a beneficial physiological effect. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of the food constituents, which are the subject of the 
claims, and a beneficial physiological effect related to stimulation of immunological responses.  
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INTRODUCTION 
The Commission has agreed with EU Member States that a certain number of Article 13 health claims 
would be eligible for further assessment by EFSA in order to be able to take a final decision on 
whether or not to include these claims in the list of permitted health claims. These claims include 
already assessed claims related to micro-organisms which the Panel considered to be not sufficiently 
characterised and claims for which the NDA Panel concluded that there was insufficient evidence to 
establish a cause and effect relationship between the consumption of the food and the claimed effect. 
Following an opinion of the NDA Panel pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 in 
which the Panel concluded that the data available were not sufficient to characterise Bifidobacterium 
animalis subsp. lactis THT 010801 (ID 960, 961, 962), Bifidobacterium longum subsp. infantis THT 
010201 (ID 967, 968), Bifidobacterium longum THT 010301 (ID 969, 970), Bifidobacterium 
pseudolongum subsp. pseudolongum THT 010501 (ID 971, 972), Lactobacillus casei THT 030401 (ID 
975, 976), Lactobacillus gasseri THT 031301 (ID 983, 984), Lactobacillus helveticus THT 031102 
(ID 985, 986), Lactobacillus plantarum THT 030701 (ID 994, 995), Lactobacillus plantarum THT 
030707 (ID 996, 997), Lactobacillus reuteri THT 030802 (ID 998, 999), Lactobacillus salivarius THT 
031001 (ID 1006, 1007) and Streptococcus thermophilus THT 070102 (ID 1014, 1015) (EFSA Panel 
on Dietetic Products Nutrition and Allergies (NDA), 2009), EFSA received additional information 
from the competent Authority of Belgium for the further assessment of this claim. The information 
provided in the framework of the further assessment for the health claims which are the subject of this 
opinion is tabulated in Appendix C. 
ASSESSMENT 
1. Characterisation of the food/constituent 
1.1. Bifidobacterium animalis subsp. lactis THT 010801 (ID 960, 961, 962) 
The food constituent that is the subject of the proposed health claims is Bifidobacterium animalis 
subsp. lactis THT 010801.  
The strain B. animalis subsp. lactis THT 010801 is the trade name for B. animalis subsp. lactis LMG 
18314, which is the type strain of B. animalis subsp. lactis. Culture collection numbers from different 
internationally recognised culture collections (e.g. LMG 18314, DSM 10140) were provided. Data on 
the identification and characterisation of B. animalis subsp. lactis THT 010801 at species and strain 
level, by using different phenotypic (carbohydrate fermentation pattern, PAGE) and genotypic (DNA-
DNA hybridisation, 16S rRNA gene sequence analysis, 16S/23S intergenic spacer region sequence 
analysis, plasmidic profile, species-specific PCR, ARDRA, Rep-PCR, AFLP, ribotyping, MLST, 
RAPD and PFGE) methods, were provided (Alander et al., 2001; Crittenden et al., 2001; Duez et al., 
2000; Masco et al., 2004; Matto et al., 2004; Roy and Sirois, 2000; Ventura and Zink, 2002; Ventura 
et al., 2006).  
The Panel considers that the food constituent that is the subject of the proposed health claims, 
B. animalis subsp. lactis THT 010801, is sufficiently characterised.  
1.2. Bifidobacterium longum subsp. infantis THT 010201 (ID 967, 968) 
The food constituent that is the subject of the proposed health claims is Bifidobacterium longum subsp. 
infantis THT 010201.  
For B. longum subsp. infantis THT 010201, a culture collection number from the Belgian 
Co-ordinated Collections of Microorganisms (LMG 25627) was provided. The BCCM/LMG is an 
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
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internationally recognised culture collection which has the status of an International Depositary 
Authority under the Budapest Treaty. In the LMG, cultures can be deposited in a restricted-access 
collection for safe deposit or for patent purposes. Data on the identification and characterisation of B. 
longum subsp. infantis THT 010201 at species and strain level, by using different phenotypic (cell 
morphology, enzymatic activities) and genotypic (16S rRNA gene sequence analysis and AFLP) 
methods, were provided in the applications for further assessment and in the accompanying references 
(BCCM/LMG, 2011a, unpublished).  
The Panel considers that the food constituent that is the subject of the proposed health claims, 
B. longum subsp. infantis THT 010201, is sufficiently characterised.  
1.3. Bifidobacterium longum subsp. longum THT 010301 (ID 969, 970) 
The food constituent that is the subject of the proposed health claims is Bifidobacterium longum subsp. 
longum THT 010301. 
For B. longum subsp. longum THT 010301, a culture collection number from the Belgian 
BCCM/LMG, LMG 26652, was provided. Data on the identification and characterisation of B. longum 
subsp. longum THT 010301 at species and strain level, by using different phenotypic (cell 
morphology, enzymatic activities) and genotypic (16S rRNA gene sequence analysis, AFLP) methods, 
were provided in the applications for further assessment and in the accompanying references 
(BCCM/LMG, 2011a, unpublished).  
The Panel considers that the food constituent that is the subject of the proposed health claims, 
B. longum subsp. longum THT 010301, is sufficiently characterised.  
1.4. Bifidobacterium pseudolongum subsp. pseudolongum THT 010501 (ID 971, 972) 
The food constituent that is the subject of the proposed health claims is Bifidobacterium 
pseudolongum subsp. pseudolongum THT 010501. 
The strain B. pseudolongum subsp. pseudolongum THT 010501 is the trade name for B. pseudolongum 
subsp. pseudolongum LMG 11571, which is the type strain of B. pseudolongum subsp. pseudolongum. 
Culture collection numbers from different internationally recognised culture collections (e.g. LMG 
11571, ATCC 25526, DSM 20099) were provided. Data on the identification and characterisation of 
B. pseudolongum subsp. pseudolongum THT 010501 at species and strain level, by using different 
genotypic (16S rRNA gene sequence analysis, 16S/23S intergenic spacer region sequence analysis, 
Hsp60 sequence analysis, Rep-PCR, MLST) methods, were provided (Jian et al., 2001; Leblond-
Bourget et al., 1996; Masco et al., 2003; Ventura et al., 2006). 
The Panel considers that the food constituent that is the subject of the proposed health claims, 
B. pseudolongum subsp. pseudolongum THT 010501, is sufficiently characterised. 
1.5. Lactobacillus casei THT 030401 (ID 975, 976) 
The food constituent that is the subject of the proposed health claims is Lactobacillus casei 
THT 030401. 
The strain L. casei THT 030401 is the trade name for L. casei LMG 6904, which is the type strain of 
L. casei. Culture collection numbers from different internationally recognised culture collections 
(e.g. LMG 6904, ATCC 393, DSM 20011) were provided. Data on the identification and 
characterisation of L. casei THT 030401 at species and strain level, by using different phenotypic 
(carbohydrate fermentation profile and PFGE) and genotypic (DNA-DNA hybridisation, 16S/23S 
rRNA intergenic spacer region sequence analysis, recombinase A and elongation factor tuf gene 
sequence analyses, species–specific PCR and RAPD) methods, were provided (Chavagnat et al., 2002; 
Dicks et al., 1996; Felis et al., 2001; Song et al., 2000; Wayne, 1994). 
Health claims related to various microorganisms (further assessment) 
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The Panel considers that the food constituent that is the subject of the proposed health claims, L. casei 
THT 030401, is sufficiently characterised. 
1.6. Lactobacillus gasseri THT 031301 (ID 983, 984) 
The food constituent that is the subject of the proposed health claims is Lactobacillus gasseri 
THT 031301.  
For L. gasseri THT 031301, a culture collection number from the BCCM/LMG, LMG 26661, was 
provided. Data on the identification and characterisation of L. gasseri THT 031301 at species and 
strain level, by using different phenotypic (cell morphology, enzymatic activities) and genotypic (16S 
rRNA gene sequence analysis and AFLP) methods, were provided in the applications for further 
assessment and in the accompanying references (BCCM/LMG, 2011b, unpublished).  
The Panel considers that the food constituent that is the subject of the proposed health claims, 
L. gasseri THT 031301, is sufficiently characterised. 
1.7. Lactobacillus helveticus THT 031102 (ID 985, 986) 
The food constituent that is the subject of the proposed health claims is Lactobacillus helveticus THT 
031102.  
For L. helveticus THT 031102, a culture collection number from the BCCM/LMG, LMG 26307, was 
provided. Data on the identification and characterisation of L. helveticus THT 031102 at species and 
strain level, by using different phenotypic (cell morphology, enzymatic activities) and genotypic (16S 
rRNA gene sequence analysis and AFLP) methods, were provided in the applications for further 
assessment and in the accompanying references (BCCM/LMG, 2011a, unpublished).  
The Panel considers that the food constituent that is the subject of the proposed health claims, 
L. helveticus THT 031102, is sufficiently characterised. 
1.8. Lactobacillus plantarum THT 030701 (ID 994, 995) 
The food constituent that is the subject of the proposed health claims is Lactobacillus plantarum THT 
030701. 
For L. plantarum THT 030701, a culture collection number from the BCCM/LMG, LMG 26654, was 
provided. Data on the identification and characterisation of L. plantarum THT 030701 at species and 
strain level, by using different phenotypic (cell morphology, enzymatic activities) and genotypic (16S 
rRNA gene sequence analysis and AFLP) methods, were provided in the applications for further 
assessment and in the accompanying references (BCCM/LMG, 2011a, unpublished).  
The Panel considers that the food constituent that is the subject of the proposed health claims, 
L. plantarum THT 030701, is sufficiently characterised. 
1.9. Lactobacillus plantarum THT 030707 (ID 996, 997) 
The food constituent that is the subject of the proposed health claims is Lactobacillus plantarum THT 
030707. 
For L. plantarum THT 030707, a culture collection number from the BCCM/LMG, LMG 26655, was 
provided. Data on the identification and characterisation of L. plantarum THT 030707 at species and 
strain level, by using different phenotypic (cell morphology, enzymatic activities) and genotypic (16S 
rRNA gene sequence analysis and AFLP) methods, were provided in the applications for further 
assessment and accompanying references (BCCM/LMG, 2011a, unpublished).  
Health claims related to various microorganisms (further assessment) 
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The Panel considers that the food constituent that is the subject of the proposed health claims, 
L. plantarum THT 030707, is sufficiently characterised. 
1.10. Lactobacillus reuteri THT 030802 (ID 998, 999) 
The food constituent that is the subject of the proposed health claims is Lactobacillus reuteri 
THT 030802. 
The strain L. reuteri THT 030802 is the trade name for L. reuteri LMG 9213, which is the type strain 
of L. reuteri. Culture collection numbers from different internationally recognised culture collections 
(e.g. LMG 9213, ATCC 23272, DSM 20016) were provided. Data on the identification and 
characterisation of L. reuteri THT 030802 at species and strain level, by using different phenotypic 
(carbohydrate fermentation profiles) and genotypic (16S rRNA gene sequence analysis, 16S/23S 
intergenic spacer region sequence analysis, elongation factor tuf gene sequence analysis, species-
specific PCR, REA, Rep-PCR and RAPD) methods, were provided (Chavagnat et al., 2002; Johansson 
et al., 1995; Kostinek et al., 2005; Kwon et al., 2004; Song et al., 2000; Yeung et al., 2002).  
The Panel considers that the food constituent that is the subject of the proposed health claims, 
L. reuteri THT 030802, is sufficiently characterised.  
1.11. Lactobacillus salivarius THT 031001 (ID 1006, 1007) 
The food constituent that is the subject of the proposed health claims is Lactobacillus salivarius THT 
031001. 
The strain L. salivarius THT 031001 is the trade name for L. salivarius LMG 9477, which is the type 
strain of L. salivarius. Culture collection numbers from different internationally recognised culture 
collections (e.g. LMG 9477, DSM 20555) were provided. Data on the identification and 
characterisation of L. salivarius THT 031001 at species and strain level, by using different phenotypic 
(carbohydrate fermentation profiles) and genotypic (16S rRNA gene sequence analysis, 16S/23S 
intergenic spacer region sequence analysis, chaperoin groEL gene sequence analyses, PFGE) methods, 
were provided (Li et al., 2006; Rogosa et al., 1953; Takizawa et al., 1994).  
The Panel considers that the food constituent that is the subject of the proposed health claims, 
L. salivarius THT 031001, is sufficiently characterised.  
1.12. Streptococcus thermophilus THT 070102 (ID 1014, 1015) 
The food constituent that is the subject of the proposed health claims is Streptococcus thermophilus 
THT 070102. 
For S. thermophilus THT 070102, a culture collection number from the BCCM/LMG, LMG 26656, 
was provided. Data on the identification and characterisation of S. thermophilus THT 070102 at 
species and strain level, by using different phenotypic (cell morphology, enzymatic activities) and 
genotypic (16S rRNA gene sequence analysis and AFLP) methods, were provided in the applications 
for further assessment and in the references provided (BCCM/LMG, 2011a, unpublished).  
The Panel considers that the food constituent that is the subject of the proposed health claims, 
S. thermophilus THT 070102, is sufficiently characterised. 
2. Relevance of the claimed effect to human health 
2.1. Changes in bowel function, and digestion and absorption of nutrients (ID 960, 961, 967, 
969, 971, 975, 983, 985, 994, 996, 998, 1006, 1014) 
The claimed effects, which are proposed for further assessment, are: “The micro-organisms are 
known, for a long time, for their intestinal impact. Indeed, the bacteria promote the digestive health by 
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several ways. Among other thing, they degrade indigestible substances (sugars, etc.) into lactic acid 
and volatile fatty acids. They participate in mobility intestinal. They contribute to the secretion and 
absorption of nutrients”, and “The micro-organisms are known, for a long time, for their intestinal 
impact. Indeed, the bacteria improve the intestinal transit, especially by their participation in mobility 
intestinal. In more, they participate to the degradation of some indigestible substances and their 
absorption by the bowel.” The proposed target population is the general population. 
The Panel notes that the claimed effect “contribute to the secretion and absorption of nutrients” is not 
sufficiently defined, and from the references provided it was not possible to establish for which 
nutrients an improved digestion and absorption is claimed. 
The Panel assumes that the claimed effect “degrade indigestible substances (sugars, etc.) into lactic 
acid and volatile fatty acids” refers to changes in short chain fatty acid (SCFA) and lactic acid 
production. The Panel considers that changes in SCFA and lactic acid production in the 
gastro-intestinal tract are not beneficial physiological effects per se, but need to be linked to a 
beneficial physiological or clinical outcome.  
The Panel assumes that the claimed effects “they participate in mobility intestinal” and “improve the 
intestinal transit” refer to changes in bowel function. The Panel considers that changes in bowel 
function such as reduced transit time, more frequent bowel movements, increased faecal bulk, or softer 
stools may be a beneficial physiological effect, provided that these changes do not result in diarrhoea. 
2.2. Decreasing potentially pathogenic gastro-intestinal microorganisms (ID 960, 967, 969, 
971, 975, 983, 985, 994, 996, 998, 1006, 1014) 
The claimed effect, which is proposed for further assessment, is: “The bacteria modulate also intestinal 
flora. They have a protective function by competitive inhibition on pathogen (competing for growth). 
They inhibit too the adhesion of these pathogens by site occupation and by production of anti-
microbial substances”. The proposed target population is the general population. 
The Panel assumes that the claimed effect refers to a decrease in potentially pathogenic 
gastro-intestinal microorganisms. The Panel considers that decreasing potentially pathogenic gastro-
intestinal microorganisms might be a beneficial physiological effect. 
2.3. Stimulation of immunological responses (ID 962, 968, 970, 972, 976, 984, 986, 995, 997, 
999, 1007, 1015) 
The claimed effect, which is proposed for further assessment, is: “A lot of study is shown an impact of 
bacteria on immune system. They improve, for example, the immune function by induction of various 
molecules and by modification of activity of some cells. The bacteria modulate also the natural 
defences. Indeed, they stimulate the natural defence by their presence or by production of some 
compounds”. The proposed target population is the general population. 
The Panel notes that the claimed effect “modulation of the natural defences” is not sufficiently 
defined, and assumes that the claimed effect relates to the stimulation of various immunological 
responses. The Panel notes that stimulation of various immunological responses is not a beneficial 
physiological effect per se but needs to be linked to a beneficial physiological or clinical outcome. 
No human studies which investigated the effect of the food constituent on any aspect of the immune 
system were provided in relation to any of the claims evaluated in this section.  
Most of the references provided were on strains or combination of strains other than those which are 
the subject of the claims.  
For ID 972, one in vitro study on the specific strain that is the subject of the claim, which investigated 
a health outcome (i.e. inhibitory effect of the strain on the adhesion of Escherichia coli O157:H7 to a 
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human epithelial cell line) (Gagnon et al., 2004) unrelated to the claimed effect evaluated in this 
section, was provided. 
For ID 976, one study in animals which investigated the effects of the specific strain that is the subject 
of the claim on antibody production (IgG and IgM) after oral immunisation with recombinant tetanus 
toxin fragment C (Plant and Conway, 2002), and one in vitro study on the activation pattern of 
dendritic cells and the impact on T cell-dependent cytokine production from healthy and allergic 
donors (Ratajczak et al., 2007), were provided.  
For ID 999, one in vitro study which investigated the effect of the specific strain that is the subject of 
the claim on the induction of cytokine secretion from splenic mononuclear cells isolated from mice 
(Matsuguchi et al., 2003) was provided.  
The Panel considers that the evidence provided does not establish that stimulation of these 
immunological responses is a beneficial physiological effect. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food constituents, which are the subject of the claims evaluated in this section, and 
a beneficial physiological effect related to stimulation of immunological responses.  
3. Scientific substantiation of the claimed effect 
3.1. Changes in bowel function (ID 960, 961, 967, 969, 971, 975, 983, 985, 994, 996, 998, 1006, 
1014)  
Most of the references provided in relation to these claims were on bacterial strains or combinations of 
strains other than those which are the subject of the claims, or on strains in combination with other 
substances or on microorganisms for which information on the genus only was given. Narrative 
reviews on the survival of bacterial strains through the stomach and small intestine, on the isolation 
and selection of bacterial strains, and on the potential use of recombinant dietary lactic acid bacteria 
for the production of oral vaccines, which were unrelated to the claim, were also provided. The Panel 
considers that no conclusions can be drawn from these references for the scientific substantiation of 
the claim. 
One human intervention study on detection of the bacterial strain in faeces (Duez et al., 2000); animal 
or in vitro studies on induction of cytokine expression (Matsuguchi et al., 2003), inhibition of 
Escherichia coli urinary tract infections (Asahara et al., 2001), inhibition of Escherichia coli O157:H7 
adhesion to human epithelial cells (Gagnon et al., 2004), protection against Listeria monocytogenes 
infection (Sato, 1984)); and/or animal and in vitro studies which addressed the potential use of a 
recombinant bacterial strain as carrier of proteins of immunological interest to intestinal mucosa 
mainly for the production of oral vaccines (Araujo Aires et al., 2006; Hazebrouck et al., 2006; Oliveira 
et al., 2006; Pant et al., 2006); and/or in vitro studies on the properties of the bacterial strains 
(e.g. survival capacity, growth at different temperatures and pH levels, viability in simulated gastro-
intestinal, bile or pancreatic conditions; adhesion to human epithelial cells or to mucus from pig small 
intestine) (Crittenden et al., 2001; Crociani et al., 1995; Gagnon et al., 2004; Jonsson et al., 2001; 
Matsumoto et al., 2004; Matto et al., 2004; McMaster et al., 2005; Miyoshi et al., 2006; Todoriki et al., 
2001) were also provided. The Panel notes that these studies did not address outcome measures related 
to the claimed effect, and considers that no conclusions can be drawn from these studies for the 
scientific substantiation of the claim. 
The Panel notes that no human studies were provided from which conclusions could be drawn for the 
scientific substantiation of the claims evaluated in this section. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food constituents which are the subject of the claims evaluated in this section and 
changes in bowel function. 
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3.2. Decreasing potentially pathogenic gastro-intestinal microorganisms (ID 960, 967, 969, 
971, 975, 983, 985, 994, 996, 998, 1006, 1014) 
Most of the references provided in relation to these claims were on bacterial strains or combinations of 
strains other than those which are the subject of the claims, or on strains in combination with other 
substances. Narrative reviews on the survival of bacterial strains through the stomach and small 
intestine, on the isolation and selection of bacterial strains, and on the potential use of recombinant 
dietary lactic acid bacteria for the production of oral vaccines, which were unrelated to the claim, were 
also provided. The Panel considers that no conclusions can be drawn from these references for the 
scientific substantiation of the claim. 
Animal studies on induction of cytokine expression (Matsuguchi et al., 2003), on inhibition of 
Escherichia coli urinary tract infections (Asahara et al., 2001), and/or in vitro studies on the properties 
of the bacterial strains (i.e. survival capacity, growth at different temperatures and pH levels, viability 
in simulated gastro-intestinal, bile or pancreatic conditions; adhesion to human epithelial cells or to 
mucus from pig small intestine) (Crittenden et al., 2001; Crociani et al., 1995; Gagnon et al., 2004; 
Jonsson et al., 2001; Matsumoto et al., 2004; Matto et al., 2004; McMaster et al., 2005; Miyoshi et al., 
2006; Todoriki et al., 2001), were also provided. In vitro and in vivo studies in animals which 
addressed the potential use of recombinant bacterial strains as carriers of proteins of immunological 
interest to intestinal mucosa mainly for the production of oral vaccines (Araujo Aires et al., 2006; 
Hazebrouck et al., 2006; Oliveira et al., 2006; Pant et al., 2006) were provided for ID 975. The Panel 
notes that these studies did not address outcome measures related to the claimed effect, and considers 
that no conclusions can be drawn from these studies for the scientific substantiation of the claim. 
The Panel notes that no human studies were provided from which conclusions could be drawn for the 
scientific substantiation of the claims evaluated in this section. 
For ID 971, an in vitro study investigated the inhibition of Escherichia coli O157:H7 adhesion to a 
human epithelial cell line in the presence of the bacterial strain that is the subject of the claim (Gagnon 
et al., 2004). For ID 975, a study in animals investigated the protective activity of the bacterial strain 
that is the subject of the claim against Listeria monocytogenes infection (Sato, 1984). The Panel 
considers that in the absence of evidence for an effect on decreasing potentially pathogenic gastro-
intestinal microorganisms in humans, evidence provided in animal and in vitro studies cannot be used 
alone for the scientific substantiation of a claim on decreasing potentially pathogenic gastro-intestinal 
microorganisms. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food constituents which are the subject of the claims evaluated in this section and 
decreasing potentially pathogenic gastro-intestinal microorganisms.  
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The following food constituents are sufficiently characterised: 
Bifidobacterium animalis subsp. lactis THT 010801 (ID 960, 961, 962), 
Bifidobacterium longum subsp. infantis THT 010201 (ID 967, 968), 
Bifidobacterium longum subsp. longum THT 010301 (ID 969, 970), 
Bifidobacterium pseudolongum subsp. pseudolongum THT 010501 (ID 971, 972), 
Lactobacillus casei THT 030401 (ID 975, 976), 
Lactobacillus gasseri THT 031301 (ID 983, 984), 
Lactobacillus helveticus THT 031102 (ID 985, 986), 
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Lactobacillus plantarum THT 030701 (ID 994, 995), 
Lactobacillus plantarum THT 030707 (ID 996, 997), 
Lactobacillus reuteri THT 030802 (ID 998, 999), 
Lactobacillus salivarius THT 031001 (ID 1006, 1007), 
Streptococcus thermophilus THT 070102 (ID 1014, 1015). 
Changes in bowel function, and digestion and absorption of nutrients (ID 960, 961, 967, 969, 971, 
975, 983, 985, 994, 996, 998, 1006, 1014) 
 The claimed effects proposed for further assessment relate to “contribute to the secretion and 
absorption of nutrients”, “degrade indigestible substances (sugars, etc.) into lactic acid and 
volatile fatty acids”, “they participate in mobility intestinal” and “improve the intestinal 
transit”. The claimed effect “contribute to the secretion and absorption of nutrients” is not 
sufficiently defined and it was not possible to establish for which nutrients an improved 
digestion and absorption is claimed. The claimed effect “degrade indigestible substances 
(sugars, etc.) into lactic acid and volatile fatty acids” is assumed to refer to changes in short 
chain fatty acid (SCFA) and lactic acid production. Changes in SCFA and lactic acid 
production in the gastro-intestinal tract are not beneficial physiological effects per se, but need 
to be linked to a beneficial physiological or clinical outcome. The claimed effects “they 
participate in mobility intestinal” and “improve the intestinal transit” are assumed to refer to 
changes in bowel function. The proposed target population is the general population. Changes 
in bowel function such as reduced transit time, more frequent bowel movements, increased 
faecal bulk, or softer stools may be a beneficial physiological effect, provided that these 
changes do not result in diarrhoea. 
 A cause and effect relationship has not been established between the consumption of the food 
constituents which are the subject of the claims and changes in bowel function. 
Decreasing potentially pathogenic gastro-intestinal microorganisms (ID 960, 967, 969, 971, 975, 
983, 985, 994, 996, 998, 1006, 1014) 
 The claimed effect proposed for further assessment relates to a decrease in potentially 
pathogenic gastro-intestinal microorganisms. The proposed target population is the general 
population. Decreasing potentially pathogenic gastro-intestinal microorganisms might be a 
beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of the food 
constituents which are the subject of the claims and decreasing potentially pathogenic gastro-
intestinal microorganisms. 
Stimulation of immunological responses (ID 962, 968, 970, 972, 976, 984, 986, 995, 997, 999, 1007, 
1015) 
 The claimed effect proposed for further assessment relates to the stimulation of various 
immunological responses. The proposed target population is the general population. The 
evidence provided did not establish that stimulation of immunological responses is a 
beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of the food 
constituents, which are the subject of the claims, and a beneficial physiological effect related 
to stimulation of immunological responses.  
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DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 for further assessment (No: 
EFSA-Q-2012-00133, EFSA-Q-2012-00134, EFSA-Q-2012-00135, EFSA-Q-2012-00136, EFSA-Q-
2012-00137, EFSA-Q-2012-00138, EFSA-Q-2012-00139, EFSA-Q-2012-00140, EFSA-Q-2012-
00141, EFSA-Q-2012-00142, EFSA-Q-2012-00143, EFSA-Q-2012-00144, EFSA-Q-2012-00145, 
EFSA-Q-2012-00146, EFSA-Q-2012-00147, EFSA-Q-2012-00148, EFSA-Q-2012-00149, EFSA-Q-
2012-00150, EFSA-Q-2012-00151, EFSA-Q-2012-00152, EFSA-Q-2012-00153, EFSA-Q-2012-
00154, EFSA-Q-2012-00155, EFSA-Q-2012-00158, EFSA-Q-2012-00159). The scientific 
substantiation is based on the information provided by the competent Authority of Belgium for the 
further assessment of this claim (available at: 
http://www.efsa.europa.eu/en/topics/topic/article13.htm). 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
5
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health".  
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be:  
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3).  
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
6
  
Foods are commonly involved in many different functions
7
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to a 
single food is scientifically pertinent.  
It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect.  
                                                     
5  OJ L12, 18/01/2007 
6  The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
7  The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).   
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SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific data, 
and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of the 
application for authorisation of health claims consistent criteria for the potential sources of scientific 
data. Such sources may not be available for all health claims. Nevertheless it will be relevant and 
important that EFSA comments on the availability and quality of such data in order to allow the 
regulator to judge and make a risk management decision about the acceptability of health claims 
included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not enough 
to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. Moreover, 
the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially affect identified 
functions in the body in a way which is relevant to health. Although an appreciation of the beneficial 
effect in relation to the nutritional status of the European population may be of interest, the presence or 
absence of the actual need for a nutrient or other substance with nutritional or physiological effect for 
that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic or 
cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of the 
body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which specifies 
this by using the word "flexibility". 
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The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore be 
specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings should 
be avoided. To this end, wordings like "strengthens your natural defences" or "contain antioxidants" 
should be considered as well as "may" or "might" as opposed to words like "contributes", "aids" or 
"helps".  
In addition, for functions affected by a large number of dietary factors it should be considered whether 
wordings such as "indispensable", "necessary", "essential" and "important" reflects the strength of the 
scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects:  
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally accepted 
scientific evidence by taking into account the totality of the available scientific data, and by 
weighing the evidence. In this context EFSA is invited to comment on the nature and quality 
of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent.  
In addition, EFSA should consider the claimed effect on the function, and provide advice on the extent 
to which: 
 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
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 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Health claims related to various microorganisms, including conditions of use, as proposed in the framework of further assessment. 
ID Food or Food constituent Health Relationship Proposed wording 
960 Bifidobacterium animalis 
subsp. lactis THT 010801 
The micro-organisms are known, for a long time, for their intestinal impact. 
Indeed, the bacteria promote the digestive health by several ways. Among other 
thing, they degrade indigestible substances (sugars, etc.) into lactic acid and 
volatile fatty acids. They participate in mobility intestinal. They contribute to the 
secretion and absorption of nutrients. 
The bacteria modulate also intestinal flora. They have a protective function by 
competitive inhibition on pathogen (competing for growth). They inhibit too the 
adhesion of these pathogens by site occupation and by production of anti-microbial 
substances. 
Maintains/restores the balance of 
intestinal flora  
Promotes intestinal comfort 
Strengthens resistance of organism 
Improves digestive health 
Conditions of use 
At least 10 E+8 CFU/day. The target population is the normal population, child and sick person not included. 
ID Food or Food constituent Health Relationship Proposed wording 
961 Bifidobacterium animalis 
subsp. lactis THT 010801 
The micro-organisms are known, for a long time, for their intestinal impact. 
Indeed, the bacteria improve the intestinal transit, especially by their participation 
in mobility intestinal. In more, they participate to the degradation of some 
indigestible substances and their absorption by the bowel 
Helps to improve intestinal transit  
Helps to reduce natural digestion  
Helps to regulate intestinal flora  
Promotes intestinal comfort 
Conditions of use 
At least 10 E+8 CFU/day. The target population is the normal population, child and sick person not included 
ID Food or Food constituent Health Relationship Proposed wording 
962 Bifidobacterium animalis 
subsp. lactis THT 010801 
A lot of study is shown an impact of bacteria on immune system. They improve, 
for example, the immune function by induction of various molecules and by 
modification of activity of some cells. 
The bacteria modulate also the natural defences. Indeed, they stimulate the natural 
defence by their presence or by production of some compounds. 
Helps to strengthen natural defences  
Stimulates immune system  
Strengthens resistance of organism 
Conditions of use 
At least 10 E+8 CFU/day. The target population is the normal population, child and sick person not included. 
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ID Food or Food constituent Health Relationship Proposed wording 
967 Bifidobacterium longum 
subsp. infantis THT 010201 
The micro-organisms are known, for a long time, for their intestinal impact. 
Indeed, the bacteria promote the digestive health by several ways. Among other 
thing, they degrade indigestible substances (sugars, etc.) into lactic acid and 
volatile fatty acids. They participate in mobility intestinal. They contribute to the 
secretion and absorption of nutrients. 
The bacteria modulate also intestinal flora. They have a protective function by 
competitive inhibition on pathogen (competing for growth). They inhibit too the 
adhesion of these pathogens by site occupation and by production of anti-microbial 
substances 
Maintains/restores the balance of 
intestinal flora  
Promotes intestinal comfort  
Strengthens resistance of organism  
Improves digestive health 
Conditions of use 
At least 10 E+8 CFU/day. The target population is the normal population, child and sick person not included. 
ID Food or Food constituent Health Relationship Proposed wording 
968 Bifidobacterium longum 
subsp. infantis THT 010201 
A lot of study is shown an impact of bacteria on immune system. They improve, 
for example, the immune function by induction of various molecules and by 
modification of activity of some cells. 
The bacteria modulate also the natural defences. Indeed, they stimulate the natural 
defence by their presence or by production of some compounds. 
Helps to strengthen natural defences  
Stimulates immune system  
Strengthens resistance of organism 
Conditions of use 
At least 10 E+8 CFU/day. The target population is the normal population, child and sick person not included. 
ID Food or Food constituent Health Relationship Proposed wording 
969 Bifidobacterium longum 
subsp. longum THT 010301 
The micro-organisms are known, for a long time, for their intestinal impact. 
Indeed, the bacteria promote the digestive health by several ways. Among other 
thing, they degrade indigestible substances (sugars, etc.) into lactic acid and 
volatile fatty acids. They participate in mobility intestinal. They contribute to the 
secretion and absorption of nutrients. 
The bacteria modulate also intestinal flora. They have a protective function by 
competitive inhibition on pathogen (competing for growth). They inhibit too the 
adhesion of these pathogens by site occupation and by production of anti-microbial 
substances. 
Maintains/restores the balance of 
intestinal flora  
Promotes intestinal comfort  
Strengthens resistance of organism  
Improves digestive health 
Conditions of use 
At least 10 E+8 CFU/day. The target population is the normal population, child and sick person not included. 
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ID Food or Food constituent Health Relationship Proposed wording 
970 Bifidobacterium longum 
subsp. longum THT 010301 
A lot of study is shown an impact of bacteria on immune system. They improve, 
for example, the immune function by induction of various molecules and by 
modification of activity of some cells. 
The bacteria modulate also the natural defences. Indeed, they stimulate the natural 
defence by their presence or by production of some compounds. 
Helps to strengthen natural defences  
Stimulates immune system  
Strengthens resistance of organism 
Conditions of use 
At least 10 E+8 CFU/day 
ID Food or Food constituent Health Relationship Proposed wording 
971 Bifidobacterium 
pseudolongum subsp. 
pseudolongum THT 010501 
The micro-organisms are known, for a long time, for their intestinal impact. 
Indeed, the bacteria promote the digestive health by several ways. Among other 
thing, they degrade indigestible substances (sugars, etc.) into lactic acid and 
volatile fatty acids. They participate in mobility intestinal. They contribute to the 
secretion and absorption of nutrients. 
The bacteria modulate also intestinal flora. They have a protective function by 
competitive inhibition on pathogen (competing for growth). They inhibit too the 
adhesion of these pathogens by site occupation and by production of anti-microbial 
substances. 
Maintains/restores the balance of 
intestinal flora  
Promotes intestinal comfort 
Strengthens resistance of organism 
Improves digestive health 
Conditions of use 
At least 10 E+8 CFU/day. The target population is the normal population, child and sick person not included. 
ID Food or Food constituent Health Relationship Proposed wording 
972 Bifidobacterium 
pseudolongum subsp. 
pseudolongum THT 010501 
A lot of study is shown an impact of bacteria on immune system. They improve, 
for example, the immune function by induction of various molecules and by 
modification of activity of some cells. 
The bacteria modulate also the natural defences. Indeed, they stimulate the natural 
defence by their presence or by production of some compounds. 
Helps to strengthen natural defences  
Stimulates immune system  
Strengthens resistance of organism 
Conditions of use 
At least 10 E+8 CFU/day. The target population is the normal population, child and sick person not included. 
ID Food or Food constituent Health Relationship Proposed wording 
975 Lactobacillus casei 
THT 030401 
The micro-organisms are known, for a long time, for their intestinal impact. 
Indeed, the bacteria promote the digestive health by several ways. Among other 
thing, they degrade indigestible substances (sugars, etc.) into lactic acid and 
Maintains/restores the balance of 
intestinal flora  
Promotes intestinal comfort 
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volatile fatty acids. They participate in mobility intestinal. They contribute to the 
secretion and absorption of nutrients. 
The bacteria modulate also intestinal flora. They have a protective function by 
competitive inhibition on pathogen (competing for growth). They inhibit too the 
adhesion of these pathogens by site occupation and by production of anti-microbial 
substances 
Strengthens resistance of organism 
Improves digestive health.  
Conditions of use 
At least 10 E+8 CFU/day. The target population is the normal population, child and sick person not included. 
ID Food or Food constituent Health Relationship Proposed wording 
976 Lactobacillus casei 
THT 030401 
A lot of study is shown an impact of bacteria on immune system. They improve, 
for example, the immune function by induction of various molecules and by 
modification of activity of some cells. 
The bacteria modulate also the natural defences. Indeed, they stimulate the natural 
defence by their presence or by production of some compounds 
Helps to strengthen natural defences  
Stimulates immune system  
Strengthens resistance of organism 
Conditions of use 
At least 10 E+8 CFU/day. The target population is the normal population, child and sick person not included. 
ID Food or Food constituent Health Relationship Proposed wording 
983 Lactobacillus gasseri 
THT 031301 
The micro-organisms are known, for a long time, for their intestinal impact. 
Indeed, the bacteria promote the digestive health by several ways. Among other 
thing, they degrade indigestible substances (sugars, etc.) into lactic acid and 
volatile fatty acids. They participate in mobility intestinal. They contribute to the 
secretion and absorption of nutrients. 
The bacteria modulate also intestinal flora. They have a protective function by 
competitive inhibition on pathogen (competing for growth). They inhibit too the 
adhesion of these pathogens by site occupation and by production of anti-microbial 
substances. 
Maintains/restores the balance of 
intestinal flora  
Promotes intestinal comfort  
Strengthens resistance of organism  
Improves digestive health 
Conditions of use 
At least 10 E+8 CFU/day. The target population is the normal population, child and sick person not included. 
ID Food or Food constituent Health Relationship Proposed wording 
984 Lactobacillus gasseri 
THT 031301 
A lot of study is shown an impact of bacteria on immune system. They improve, 
for example, the immune function by induction of various molecules and by 
modification of activity of some cells.  
The bacteria modulate also the natural defences. Indeed, they stimulate the natural 
Helps to strengthen natural defences  
Stimulates immune system  
Strengthens resistance of organism 
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defence by their presence or by production of some compounds. 
Conditions of use 
At least 10 E+8 CFU/day. The target population is the normal population, child and sick person not included. 
ID Food or Food constituent Health Relationship Proposed wording 
985 Lactobacillus helveticus THT 
031102 
The micro-organisms are known, for a long time, for their intestinal impact. 
Indeed, the bacteria promote the digestive health by several ways. Among other 
thing, they degrade indigestible substances (sugars, etc.) into lactic acid and 
volatile fatty acids. They participate in mobility intestinal. They contribute to the 
secretion and absorption of nutrients. 
The bacteria modulate also intestinal flora. They have a protective function by 
competitive inhibition on pathogen (competing for growth). They inhibit too the 
adhesion of these pathogens by site occupation and by production of anti-microbial 
substances. 
Maintains/restores the balance of 
intestinal flora  
Promotes intestinal comfort  
Strengthens resistance of organism  
Improves digestive health 
Conditions of use 
At least 10 E+8 CFU/day. The target population is the normal population, child and sick person not included. 
ID Food or Food constituent Health Relationship Proposed wording 
986 Lactobacillus helveticus THT 
031102 
A lot of study is shown an impact of bacteria on immune system. They improve, 
for example, the immune function by induction of various molecules and by 
modification of activity of some cells. 
The bacteria modulate also the natural defences. Indeed, they stimulate the natural 
defence by their presence or by production of some compounds. 
Maintains/restores the balance of 
intestinal flora  
Promotes intestinal comfort  
Strengthens resistance of organism  
Improves digestive health 
Conditions of use 
At least 10 E+8 CFU/day. The target population is the normal population, child and sick person not included. 
ID Food or Food constituent Health Relationship Proposed wording 
994 Lactobacillus plantarum THT 
030701 
The micro-organisms are known, for a long time, for their intestinal impact. 
Indeed, the bacteria promote the digestive health by several ways. Among other 
thing, they degrade indigestible substances (sugars, etc.) into lactic acid and 
volatile fatty acids. They participate in mobility intestinal. They contribute to the 
secretion and absorption of nutrients.  
The bacteria modulate also intestinal flora. They have a protective function by 
Maintains/restores the balance of 
intestinal flora  
Promotes intestinal comfort  
Strengthens resistance of organism  
Improves digestive health 
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competitive inhibition on pathogen (competing for growth). They inhibit too the 
adhesion of these pathogens by site occupation and by production of anti-microbial 
substances. 
Conditions of use 
At least 10 E+8 CFU/day. The target population is the normal population, child and sick person not included. 
ID Food or Food constituent Health Relationship Proposed wording 
995 Lactobacillus plantarum THT 
030701 
A lot of study is shown an impact of bacteria on immune system. They improve, 
for example, the immune function by induction of various molecules and by 
modification of activity of some cells. 
The bacteria modulate also the natural defences. Indeed, they stimulate the natural 
defence by their presence or by production of some compounds. 
Helps to strengthen natural defences  
Stimulates immune system  
Strengthens resistance of organism 
Conditions of use 
At least 10 E+8 CFU/day. The target population is the normal population, child and sick person not included. 
ID Food or Food constituent Health Relationship Proposed wording 
996 Lactobacillus plantarum THT 
030707 
The micro-organisms are known, for a long time, for their intestinal impact. 
Indeed, the bacteria promote the digestive health by several ways. Among other 
thing, they degrade indigestible substances (sugars, etc.) into lactic acid and 
volatile fatty acids. They participate in mobility intestinal. They contribute to the 
secretion and absorption of nutrients. 
The bacteria modulate also intestinal flora. They have a protective function by 
competitive inhibition on pathogen (competing for growth). They inhibit too the 
adhesion of these pathogens by site occupation and by production of anti-microbial 
substances. 
Maintains/restores the balance of 
intestinal flora  
Promotes intestinal comfort  
Strengthens resistance of organism  
Improves digestive health 
Conditions of use 
At least 10 E+8 CFU/day. The target population is the normal population, child and sick person not included. 
ID Food or Food constituent Health Relationship Proposed wording 
997 Lactobacillus plantarum THT 
030707 
A lot of study is shown an impact of bacteria on immune system. They improve, 
for example, the immune function by induction of various molecules and by 
modification of activity of some cells.  
The bacteria modulate also the natural defences. Indeed, they stimulate the natural 
defence by their presence or by production of some compounds. 
Helps to strengthen natural defences  
Stimulates immune system  
Strengthens resistance of organism 
Conditions of use 
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At least 10 E+8 CFU/day. The target population is the normal population, child and sick person not included. 
ID Food or Food constituent Health Relationship Proposed wording 
998 Lactobacillus reuteri 
THT 030802 
The micro-organisms are known, for a long time, for their intestinal impact. 
Indeed, the bacteria promote the digestive health by several ways. Among other 
thing, they degrade indigestible substances (sugars, etc.) into lactic acid and 
volatile fatty acids. They participate in mobility intestinal. They contribute to the 
secretion and absorption of nutrients.  
The bacteria modulate also intestinal flora. They have a protective function by 
competitive inhibition on pathogen (competing for growth). They inhibit too the 
adhesion of these pathogens by site occupation and by production of anti-microbial 
substances. 
Maintains/restores the balance of 
intestinal flora  
Promotes intestinal comfort 
Strengthens resistance of organism 
Improves digestive health 
Conditions of use 
At least 10 E+8 CFU/day. The target population is the normal population, child and sick person not included. 
ID Food or Food constituent Health Relationship Proposed wording 
999 Lactobacillus reuteri 
THT 030802 
A lot of study is shown an impact of bacteria on immune system. They improve, 
for example, the immune function by induction of various molecules and by 
modification of activity of some cells. 
The bacteria modulate also the natural defences. Indeed, they stimulate the natural 
defence by their presence or by production of some compounds. 
Helps to strengthen natural defences  
Stimulates immune system  
Strengthens resistance of organism 
Conditions of use 
At least 10 E+8 CFU/day. The target population is the normal population, child and sick person not included. 
ID Food or Food constituent Health Relationship Proposed wording 
1006 Lactobacillus salivarius THT 
031001 
The micro-organisms are known, for a long time, for their intestinal impact. 
Indeed, the bacteria promote the digestive health by several ways. Among other 
thing, they degrade indigestible substances (sugars, etc.) into lactic acid and 
volatile fatty acids. They participate in mobility intestinal. They contribute to the 
secretion and absorption of nutrients. 
The bacteria modulate also intestinal flora. They have a protective function by 
competitive inhibition on pathogen (competing for growth). They inhibit too the 
adhesion of these pathogens by site occupation and by production of anti-microbial 
substances. 
Maintains/restores the balance of 
intestinal flora  
Promotes intestinal comfort 
Strengthens resistance of organism 
Improves digestive health 
Conditions of use 
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- At least 10 E+8 CFU/day. The target population is the normal population, child and sick person not included. 
ID Food or Food constituent Health Relationship Proposed wording 
1007 Lactobacillus salivarius THT 
031001 
A lot of study is shown an impact of bacteria on immune system. They improve, 
for example, the immune function by induction of various molecules and by 
modification of activity of some cells. 
The bacteria modulate also the natural defences. Indeed, they stimulate the natural 
defence by their presence or by production of some compounds. 
Helps to strengthen natural defences  
Stimulates immune system  
Strengthens resistance of organism  
Conditions of use 
At least 10 E+8 CFU/day. The target population is the normal population, child and sick person not included. 
ID Food or Food constituent Health Relationship Proposed wording 
1014 Streptococcus thermophilus 
THT 070102 
The micro-organisms are known, for a long time, for their intestinal impact. 
Indeed, the bacteria promote the digestive health by several ways. Among other 
thing, they degrade indigestible substances (sugars, etc.) into lactic acid and 
volatile fatty acids. They participate in mobility intestinal. They contribute to the 
secretion and absorption of nutrients. 
The bacteria modulate also intestinal flora. They have a protective function by 
competitive inhibition on pathogen (competing for growth). They inhibit too the 
adhesion of these pathogens by site occupation and by production of anti-microbial 
substances 
Maintains/restores the balance of 
intestinal flora  
Promotes intestinal comfort 
Strengthens resistance of organism 
Improves digestive health 
Conditions of use 
At least 10 E+8 CFU/day. The target population is the normal population, child and sick person not included. 
ID Food or Food constituent Health Relationship Proposed wording 
1015 Streptococcus thermophilus 
THT 070102 
A lot of study is shown an impact of bacteria on immune system. They improve, 
for example, the immune function by induction of various molecules and by 
modification of activity of some cells. 
The bacteria modulate also the natural defences. Indeed, they stimulate the natural 
defence by their presence or by production of some compounds. 
Helps to strengthen natural defences  
Stimulates immune system  
Strengthens resistance of organism 
Conditions of use 
At least 10 E+8 CFU/day. The target population is the normal population, child and sick person not included. 
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GLOSSARY AND ABBREVIATIONS 
AFLP   Amplified fragment length polymorphism 
ARDRA  Amplified rDNA restriction analysis 
ATCC   American Type Culture Collection 
BCCM/LMG Belgian Co-ordinated Collections of Microorganisms/Laboratorium voor 
Microbiologie, Universiteit Gent 
DNA   Deoxyribonucleic acid  
MLST   Multi-locus sequence typing 
PAGE   Polyacrylamide gel electrophoresis. 
PCR   Polymerase chain reaction 
PFGE   Pulsed field gel electrophoresis 
RAPD   Randomly amplified polymorphic DNA. 
REA   Chromosomic DNA restriction analysis. 
Rep-PCR  Repetitive extragenomic palindromic – PCR 
RNA   Ribonucleic acid  
SCFA   Short chain fatty acid  
